Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (iparomlimab + tuvonralimab) plus lenvatinib as neoadjuvant therapy for high-complexity localized renal cell carcinoma
ChiCTR2500111466Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Decline rate of tumor R.E.N.A.L. score. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1706lenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2500111466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111466.